Aponia Dental

Aponia Pharmaceuticals, also operating as Aponia Dental, was a specialty pharmaceutical company focused on developing topical treatments for acute pain, with a specific emphasis on the dental market. The company's lead candidate, APN-101, was a proprietary 10% ketoprofen gel designed to provide localized analgesia for patients recovering from dental surgeries, such as third molar extractions. By delivering the medication topically, Aponia aimed to achieve effective pain relief at the site of injury while significantly reducing the systemic exposure and side effects typically associated with oral NSAIDs and opioids. The company successfully completed Phase 2 clinical trials for APN-101, demonstrating its potential as a safer alternative for post-operative pain management, though the company is no longer active.